Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Androgen biosynthesis inhibitors are crucial for prostate cancer treatment, targeting key enzymes like CYP17A1.
• Newer strategies focus on inhibiting CYP11A1, a gatekeeper enzyme in steroidogenesis, showing early promise with agents like ODM-208.
• Inhibiting androgen synthesis disrupts complex hormonal pathways, impacting the adrenal gland and renin-angiotensin-aldosterone system.

Approach:

• This review synthesizes current research on targeting androgen biosynthesis pathways in prostate cancer.
• It examines the systemic physiological consequences of these targeted therapies.
• The focus is on understanding and mitigating potential adverse effects.

Key Points:

• CYP17A1 inhibition is an established prostate cancer therapy.
• CYP11A1 inhibition is an emerging strategy with demonstrated antitumor effects.
• Targeting CYP11A1 may lead to adrenal insufficiency and cardiovascular issues due to broad adrenal cortex suppression.

Conclusions:

• Androgen biosynthesis inhibitors offer significant antitumor benefits in prostate cancer.
• Systemic implications and potential side effects, such as adrenal insufficiency, must be carefully managed.
• Balancing treatment efficacy with adverse event mitigation is key for improved patient outcomes.